Mainet-González Damian, Galván-Cabrera José A, Sorell-Gómez Luis, Torres-Cabrera Maritza B, Abdo-Cuza Anselmo, Castellano-Gutiérrez R, Padrón-Brito Nolaida, Palenzuela-Gardón Daniel, Novoa-Pérez Lidia I
Centro de Ingeniería Genética y Biotecnología de La Habana, Ciudad de La Habana, Cuba.
Invest Clin. 2004 Sep;45(3):221-42.
The cardiac Troponin I is considered the biochemical marker of election to detect acute myocardial infarction, a medical urgency that requires a rapid diagnosis. In this article, the diagnosis of this condition was studied qualitatively through an immunochromatographic assay of a single step detection of cardiac Troponin I elaborated in the laboratory comparing it with another, commercially available, qualitative immunochromatographic assay of detection of cardiac Troponin I, Cardiac STATUS TM. The plasmas of 76 patients with acute myocardial infarction and 50 plasmas obtained from healthy donors were evaluated retrospectively. The laboratory's immunoassay did not present cross reactivity with the skeletal isoform of Troponin I. This test detected 1 ng/mL or more of cardiac Troponin I in the form of a tertiary complex in plasma and it also recognized the free molecule. The clinical sensitivity of the immunoassay of the laboratory in patients with Q wave type acute myocardial infarction was 100% and for the commercial immunoassay was 85.7% in the period of 6 h to 24 h following the onset of chest pain. For this type of infarction, the signal was detected up to 148 h after the onset of symptoms and the clinical sensitivity oscillated between 84.2% and 90.9% for both assays. The clinical sensitivities of the two immunoassays were 70% in the case of patients with non-Q wave acute myocardial infarction. With healthy donor's samples, the clinical specificity of the immunochromatographic assay prepared in the laboratory was of 90.4% and for commercial immunoassay was 100%. The immunochromatographic immunoassays of a single step for the detection of cardiac Troponin I evaluated in this work, diagnosed in a quick and easy way, important myocardial cell death and to lesser extent smaller necrosis, in patients without concluding electrocardioghraphic signs and with the possibility of the occurrence of complications.
心肌肌钙蛋白I被认为是用于检测急性心肌梗死的首选生化标志物，急性心肌梗死是一种需要快速诊断的医疗急症。在本文中，通过实验室自行研制的一步法免疫层析检测心肌肌钙蛋白I的方法对该病症进行定性诊断，并将其与另一种市售的定性免疫层析检测心肌肌钙蛋白I的方法Cardiac STATUS TM进行比较。回顾性评估了76例急性心肌梗死患者的血浆和50例健康供体的血浆。实验室免疫测定法与肌钙蛋白I的骨骼肌异构体无交叉反应。该检测方法能以三级复合物的形式检测出血浆中1 ng/mL或更高浓度的心肌肌钙蛋白I，并且还能识别游离分子。在胸痛发作后的6小时至24小时内，实验室免疫测定法对Q波型急性心肌梗死患者的临床敏感性为100%，而市售免疫测定法为85.7%。对于此类梗死，症状发作后148小时仍可检测到信号，两种检测方法的临床敏感性在84.2%至90.9%之间波动。对于非Q波急性心肌梗死患者，两种免疫测定法的临床敏感性均为70%。对于健康供体样本，实验室制备的免疫层析测定法的临床特异性为90.4%，市售免疫测定法为100%。在这项研究中评估的用于检测心肌肌钙蛋白I的一步法免疫层析免疫测定法，能够快速简便地诊断出重要的心肌细胞死亡以及程度较轻的较小坏死，适用于无心电图体征且可能发生并发症的患者。
